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Transcription factorThe inv(16) translocation is associated with 5% of AML cases and gives rise to expression of the oncofusion pro-
tein CBFβ-MYH11. Although different molecular mechanisms for the oncogenic activity of this fusion protein
have been proposed these were mostly based on in vitro experiments or single loci analysis. Recently, we inves-
tigated the genome-wide action of this fusion protein in the context of other hematopoietic transcription factors
(Mandoli et al., 2014). Here, we describe in detail the ChIP-seq and RNA-seq methods used to generate the data
associated with this study. Our analysis of CBFβ-MYH11 as well as multiple other hematopoietic transcription
factors using ChIP-seq data revealed RUNX1 dependent binding of CBFβ-MYH11 as well as interaction of the
RUNX1/CBFβ-MYH11 complex with other hematopoietic regulators. Further RNA-seq based analysis suggested
that CBFβ-MYH11 can act both as activator and repressor.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).SpeciﬁcationsOrganism/cell line/tissue Homo sapiens/ME-1, inv(16) patients, U937
Sex Male
Sequencer or array type Illumina
Data format Analyzed
Experimental factors inv(16) Acute myeloid leukemia cell line, inv(16) AML
model cell lines and inv(16) AML primary patient cells
Experimental features ChIP seq and RNA seq
Consent All patients gave their consent
Sample source location Groningen, The NetherlandsDirect link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE46044
Experimental design, materials and methods
Cell culture and patient samples
In this study we used ChIP-seq to generate genome-wide binding
proﬁles of proteins in 3 cell types: ME-1 cells harboring the inv(16)
translocation and expressing the CBFβ-MYH11 oncofusion protein [5];
an inducible U937 cell line (U937CM) that on induction expresses
CBFβ-MYH11[1]; and a mononuclear CD34+ inv(16) AML blast.
. This is an open access article underpopulation isolated from peripheral blood of a de novo AML patient
which was studied after informed consent was obtained in accordance
with the Declaration of Helsinki. In addition, an inducible knockdown
cell line was generated by cloning of CBFβ-MYH11 speciﬁc shRNA in a
FH1tUTG lentiviral construct as described previously [2]. For this,
lentiviral particles were produced in Cos-7 cells after which ﬁltered
and concentrated viral supernatants were used to infect ME-1 cells.
GFP positive cells were sorted by FACS and shRNA expression was in-
duced by addition of doxycycline.
The ME-1 and U937-Tet-off CBFβ-MYH11 cells were cultured in
RPMI 1640 supplemented with 10% FCS and 1% penicillin/streptomycin
at 37 °C in 5% CO2. For conditional expression of CBFβ-MYH11, U937
cells were washed 5 times in 50 ml phosphate-buffered saline (PBS)
and seeded at a density of 2 × 105 cells/ml in the absence of tetracycline.
The increase of CBFβ-MYH11 expression was detected by RT-PCR and
Western blot. The different cell types were used for ChIP-seq experi-
ments using different antibodies as outlined in Supplementary
Table 1. In addition, for the cell lines RNA-seq datawas generated to de-
termine the correlation between transcription factor binding and gene
expression.
Chromatin immunoprecipitation (ChIP)
For ChIP 25 million cells were crosslinkedwith 1% formaldehyde for
20 min at room temperature with trembling. The reaction was stopped
by adding 0.125 M glycine and cells were centrifuged and washed once
with PBS. Cell pellets were suspended in 50ml of buffer A (0.25% Tritonthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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at 4 °C for 10minwith rotation. The suspensionwas centrifuged and the
pellet was resuspended in 50ml of buffer B (150mMNaCl, 10mMEDTA,
0.5 mM EGTA, 20 mM HEPES pH 7.6). After 10 min rotation at 4 °C the
suspension was centrifuged and resuspended in incubation buffer
(0.15% SDS, 1% Triton X 100, 150 mM NaCl, 10 mM EDTA, 0.5 mM
EGTA, 20 mM HEPES pH 7.6 and protease inhibitor cocktail). Chromatin
was sonicated using the bioruptor (Diagenode) for 20 min at high
power, 30 s ON, 30 s OFF. Sonication is an important step of the ChIP pro-
cedure and it varies for different cell types and sonicators. To ﬁnd the
proper number of cycles for sonication, i.e. to obtain a fragment size
range between 150 and 500 base pairs, we ﬁrst performed sonication
on a fraction of the chromatin suspension. In our case, 20 cycles were
optimal for ME-1 cells, and 16 cycles were optimal for U937 cells.
Sonicated chromatin was centrifuged at 13,000 rpm for 10 min at
4 °C and supernatant was collected for ChIP. For every ChIP 100 μl of
chromatin (corresponding to 1.25 × 106 cells) was incubated overnight
at 4 °C with rotation in incubation buffer supplemented with 0.1% BSA,
protease inhibitor cocktail, 30 μl of protein A/G-sepharose beads (Santa
Cruz), and 4 μg of antibody (see Supplementary table). Beads were
washed sequentially with four different wash buffers at 4 °C: two
times with buffer 1 (0.1% SDS, 0.1% DOC, 1% Triton, 150 mM NaCl,
10mMTris pH 8, 0.1mMEDTA, and 0.5mMEGTA), one timewith buff-
er 2 (0.1% SDS, 0.1% DOC, 1% Triton, 500 mM NaCl, 10 mM Tris pH 8,
0.1 mM EDTA, and 0.5 mM EGTA), one time with buffer 3 (0.25 M LiCl,
0.5% DOC, 0.5% NP-40, 10 mM Tris pH 8, 0.1 mM EDTA, and 0.5 mM
EGTA), and two times with buffer 4 (10 mM Tris pH 8, 0.1 mM EDTA,
and 0.5 mM EGTA). The immunoprecipitated chromatin was eluted
from the beads by adding 200 μl of elution buffer (1% SDS, 0.1 M
NaHCO3, 10 μg/ml RNase and 250 μg/ml proteinase K) and rotated for
20 min at RT. Chromatin was extracted by centrifugation at maximum
speed for 2 min and protein-DNA crosslinks were reversed at 65 °C for
4 h in the presence of 200 mM NaCl, after which DNA was puriﬁed
with the QIAquick PCR puriﬁcation kit (Qiagen). For each ChIP-seq, 4–
5 ChIPs were pooled using a single column, DNA was eluted in 35 μl of
elution buffer and measured with the Qubit dsDNA HS Assay kit
(Invitrogen).
The quality of ChIPs was checked using an aliquot of the eluted DNA
in quantitative PCR (qPCR). Relative occupancy at putative CBFβ-
MYH11 binding regions was calculated as fold over background, for
which the promoter of theH2B genewas used (Fig. 1 and Supplementa-
ry Table 1 for primer sequences).
Strand speciﬁc RNA sequencing
For RNA-seq total RNA was extracted from ME-1 cells using the
RNeasy kit and on-column DNase treatment (Qiagen). The concentra-
tion of RNA was measured with the Qubit ﬂuorometer (Invitrogen).
250 ng of total RNA was used in the Ribo-Zero rRNA Removal Kit
(Epicentre) to remove ribosomal RNAs according to manufacturero
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Fig. 1. ChIP-qPCR using CBFβ and MYH11 antibodies in ME-1 cells. Five putative binding
sites of CBFβ and CBFβ-MYH11 were selected and occupancies at these sites were deter-
mined by qPCR. Data was normalized using H2B as a negative control.instructions. 16 μl of puriﬁed RNA was fragmented by addition of 4 μl
of 5× fragmentation buffer (200mMTris acetate pH 8.2, 500mMpotas-
sium acetate, and 150 mMmagnesium acetate), incubated at 94 °C for
exactly 90 s and placed on ice immediately afterwards. Fragmented
RNA was precipitated by adding 2 μl NaAC (3 M), 2 μl glycogen
(10 mg/ml) and 60 μl of absolute ethanol in 1.5 ml tubes. After mixing
by inverting, tubes were incubated at −80 °C for at least 1 h. Next,
tubes were spun at 4 °C for 30 min and supernatant was discarded.
RNA pellet was washed once with 70% ethanol, air dried for 5 min and
dissolved in 10 μl of nuclease free H2O.
5 μg random hexamers were added to the RNA followed by incuba-
tion at 70 °C for 10 min and chilling on ice. Next, ﬁrst-strand cDNA was
synthesized using a RNA primer mix and adding 4 μl of5× ﬁrst-strand
buffer, 1 μl of RNase inhibitor (Promega # N2618), 2 μl of 100 mM
DTT, 1 μl of 10 mM dNTPs, 132 ng of actinomycin D, and 200 U Super-
Script III (Invitrogen), followed by 2 hours incubation at 48 °C. First
strand cDNA was puriﬁed using Qiagen mini elute columns to remove
dNTPs and eluted two times with 17 μl of elution buffer. Second-
strand cDNA was synthesized by adding 91.8 μl of a mix containing
5 μg random hexamers, 4 μl of 5× ﬁrst-strand buffer, 2 μl of 100 mM
DTT, 4 μl of 10 mM dNTPs with dTTP replaced by dUTP, 30 μl of 5×
second-strand buffer, 40 U of Escherichia coli DNA polymerase (NEB #
M02095S), 10 U of E. coli DNA ligase (NEB # M0205L) and 2 U of
E. coli RNase H (Ambion # AM2293), and incubated at 16 °C for 2 h.
This was followed by addition of 10 U T4 polymerase (NEB # M0203)
and incubation at 16 °C for 10min. Double stranded cDNAwas puriﬁed
using Qiagen mini elute columns and an adenosine base was added to
the ends as described below for DNA obtained from ChIP experiments
to facilitate ligation. All the subsequent steps are the same for the
RNA-seq and ChIP-seq sample prep protocol (see below) other than
the addition of 1 U USER enzyme (NEB # M5505L) to RNA-seq samples
before PCR and incubation at 37 °C for 15 min, followed by 5 min at
95 °C.Illumina high throughput sequencing
For library preparation, 2–10 ng of ChIP DNA was used. End repair
was performed using 40 μl of ChIP DNA, 5 μl T4 DNA ligase buffer with
10 mM ATP, 2 μl dNTP mix (10 mM each), 1 μl of T4 DNA polymerase
(NEB # M0203L), 1 μl diluted Klenow DNA polymerase (1:5, NEB #
M0210L), and T4 PNK (NEB #M0201L) in a total volume of 50 μl and in-
cubation at 20 °C for 30 min, followed by puriﬁcation using the
QIAquick PCR puriﬁcation kit and elution in 34 μl of EB.
To prepare the DNA fragments for adaptor ligation an adenosine
base was added to the 3′ ends of the repaired DNA by addition of 5 μl
Klenow buffer, 10 μl dATP and 1 ul Klenow exo– (NEB # M0212L). The
reaction was incubated at 37 °C for 30 min followed by puriﬁcation
using the Qiagen mini elute reaction clean up kit. DNA was eluted in
10 μl of EB.
Adaptors were ligated to 10 μl of eluted DNA by addition of 15 μl of
2× T4 DNA ligase buffer, 1 μl of Nextﬂex adaptor (see the Bio Scientiﬁc
ChIP-Seq barcodes protocol for adaptor dilution; # 514120), and 4 μl T4
ligase (Promega #M180B). The reactionwas incubated at room temper-
ature for 15min. DNAwas puriﬁed using the Qiagenmini elute reaction
clean up kit, eluted in 10 μl of EB, and followed by PCR. The PCR reaction
was assembled in a total volume of 50 μl by adding 10 μl DNA, 2 μl
Nextﬂex primer, 25 μl Kapa 2× master mix (Kapa #KK2612), and 13 μl
of H2O. PCR was performed for 4 cycles using ampliﬁcation conditions
as mentioned in the Kapa protocol followed by puriﬁcation using the
Qiagen mini elute reaction clean up kit. DNA was eluted in 10 μl of EB
and size selected using an E-gel system (Invitrogen # G661002) accord-
ing to themanufacturer's protocol. 23 μl of DNAwas collected in the size
range of 290–320 bp (ChIP fragment + adapters). Size selected DNA
was PCR ampliﬁed using 2 μl Nextﬂex primer and 25 μl Kapa 2×master
mix in a total volume of 50 μl. The PCR reactionwas puriﬁed by AMPure
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Fig. 2. ChIP-seq screen shot of a CBFβ-MYH11 binding site using two antibodies, one against CBFβ and one recognizingMYH11. Overview of the CARHSP1 CBFβ-MYH11 binding site inME-
1 cells. In red the MYH11 ChIP-seq data using a Novus antibody is plotted and in blue the CBFβ data using a Santa Cruz antibody.
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EB.
DNA integrity and sizewere checked on a Bio-Rad Experionmachine
and cluster generation and sequencing by synthesis was performed on
the Illumina 1G or HiSeq genome analyzer according to Illumina in-
structions. The image ﬁles were processed using Illumina's Consensus
Assessment of Sequence and Variation (CASAVA) for base calling and
generation of FastQ ﬁle containing 35–45 bp tags. FastQ data were
mapped to the human genome HG18 using the eland or Burrows–
Wheeler Alignment Tool (BWA) program allowing 1 mismatch. For
visualization purpose 35–45 bp sequence reads were directionally ex-
tended to 300 bp, corresponding to the length of the original fragments
used for sequencing. For each base pair in the genome the number of
overlapping sequence reads was determined and averaged over a 10
bpwindow and visualized as wiggle track in the UCSC genome browser
(Fig. 2) (http://genome.ucsc.edu). Tag ﬁles as well as visualization
tracks can be found in GSE46044. In addition, peak calls (see below)
for transcription factor binding as well as expression values (RPKM,
see below) for the RNA-seq are provided as supplementary information.
Moreover, for visualization all tracks are available as trackhub: http://
trackhub.science.ru.nl/hubs/CBFb/CBFb-MYH/hub.txt.
Identiﬁcation of protein binding sites based on ChIP-seq results
Peaks (Supplementary table) were called by model-based analysis
(MACS1.3.3) of ChIP-seq [6] at a p-value cut off of 10−6 and called
regions are available in Supplementary tables.
Expression analysis
For expression analysis RPKM (reads per kilobase of gene length per
million reads) [4] values for RefSeq genes were computed using tag
counting scripts (Supplementary table) and used to analyze the expres-
sion level of genes in ME-1 and U937 cells.
Discussion
In this studywedescribed themethods used to establish the genome
wide binding proﬁle of CBFβ-MYH11 and other hematopoietictranscription factors in an inv(16) cell line, in CBFβ-MYH11 inducible
and knockdown cell lines, and in primary patient cells. The methodolo-
gy was used to investigate the mechanisms by which CBFβ-MYH11 ex-
erts its function in leukemogenesis. Our analysis, published in [3]
revealed that CBFβ-MYH11 localizes to RUNX1 occupied promoters
where it operates in the context of TBP associated factors (TAFs), the
epigenetic enzymes EP300 and HDAC1, and several hematopoietic tran-
scription factors. RNA-seq analysis in ME-1 knockdown cells revealed
that CBFβ-MYH11 is involved in both transcriptional activation and re-
pression, which was conﬁrmed by ChIP-seq and RNA-seq analysis in an
inducible U937 CBFβ-MYH11 cell system. Together these results reveal
a role for CBFβ-MYH11 in regulating expression of genes important in
inv(16) leukemogenesis.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.gdata.2014.06.014.References
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